Published in Methods Mol Biol on January 01, 2012
Retroviruses use CD169-mediated trans-infection of permissive lymphocytes to establish infection. Science (2015) 1.65
Adenovirus-Vectored Broadly Neutralizing Antibodies Directed Against gp120 Prevent Human Immunodeficiency Virus Type 1 Acquisition in Humanized Mice. Hum Gene Ther (2015) 0.75
Heart bailout by cell therapy: introducing an acceptable test for comparing cell accountability. Stem Cell Res Ther (2012) 0.75
The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. Science (1988) 9.05
Humanized mice in translational biomedical research. Nat Rev Immunol (2007) 8.83
Development of a human adaptive immune system in cord blood cell-transplanted mice. Science (2004) 7.07
Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice. Blood (2005) 6.16
Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med (2008) 5.81
Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. Nat Med (2006) 5.36
T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell (2008) 4.32
Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science (2008) 3.51
Reconstitution of a functional human immune system in immunodeficient mice through combined human fetal thymus/liver and CD34+ cell transplantation. Blood (2006) 2.94
Induction of robust cellular and humoral virus-specific adaptive immune responses in human immunodeficiency virus-infected humanized BLT mice. J Virol (2009) 2.70
Humanized mice for modeling human infectious disease: challenges, progress, and outlook. Cell Host Microbe (2009) 2.58
Complete reconstitution of human lymphocytes from cord blood CD34+ cells using the NOD/SCID/gammacnull mice model. Blood (2003) 2.53
Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1. Proc Natl Acad Sci U S A (2007) 2.27
Functional human T lymphocyte development from cord blood CD34+ cells in nonobese diabetic/Shi-scid, IL-2 receptor gamma null mice. J Immunol (2002) 1.86
Mucosal transmission of R5 and X4 tropic HIV-1 via vaginal and rectal routes in humanized Rag2-/- gammac -/- (RAG-hu) mice. Virology (2008) 1.81
Animal models of HIV-1 disease. Science (1997) 1.04
RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med (2003) 7.37
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol (2005) 6.40
siRNA-directed inhibition of HIV-1 infection. Nat Med (2002) 6.36
miRNA profiling of naïve, effector and memory CD8 T cells. PLoS One (2007) 5.43
Transvascular delivery of small interfering RNA to the central nervous system. Nature (2007) 5.21
T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell (2008) 4.32
Sustained small interfering RNA-mediated human immunodeficiency virus type 1 inhibition in primary macrophages. J Virol (2003) 2.26
Most antiviral CD8 T cells during chronic viral infection do not express high levels of perforin and are not directly cytotoxic. Blood (2002) 1.94
Lentiviral delivery of short hairpin RNAs. Adv Drug Deliv Rev (2009) 1.65
Alternative processing of primary microRNA transcripts by Drosha generates 5' end variation of mature microRNA. PLoS One (2009) 1.63
A single siRNA suppresses fatal encephalitis induced by two different flaviviruses. PLoS Med (2006) 1.55
RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice. Mol Ther (2009) 1.55
Lentiviral delivery of short hairpin RNAs protects CD4 T cells from multiple clades and primary isolates of HIV. Blood (2005) 1.54
Targeted delivery of siRNA to macrophages for anti-inflammatory treatment. Mol Ther (2010) 1.28
Interfering with disease: opportunities and roadblocks to harnessing RNA interference. Trends Mol Med (2003) 1.10
The functional CD8 T cell response to HIV becomes type-specific in progressive disease. J Clin Invest (2002) 1.09
Newer gene editing technologies toward HIV gene therapy. Viruses (2013) 1.07
Targeted delivery of small interfering RNA to human dendritic cells to suppress dengue virus infection and associated proinflammatory cytokine production. J Virol (2009) 1.06
Targeted disruption of the CCR5 gene in human hematopoietic stem cells stimulated by peptide nucleic acids. Chem Biol (2011) 1.05
Interfering antiviral immunity: application, subversion, hope? Trends Immunol (2006) 1.03
NFAT5 regulates HIV-1 in primary monocytes via a highly conserved long terminal repeat site. PLoS Pathog (2006) 0.99
Health impact assessment needs in south-east Asian countries. Bull World Health Organ (2003) 0.97
Conditional RNAi: towards a silent gene therapy. Adv Drug Deliv Rev (2009) 0.95
Human macrophage and dendritic cell-specific silencing of high-mobility group protein B1 ameliorates sepsis in a humanized mouse model. Proc Natl Acad Sci U S A (2012) 0.94
Avoiding the kiss of death: how HIV and other chronic viruses survive. Curr Opin Immunol (2002) 0.93
Identification and functional analysis of the primary pantothenate transporter, PfPAT, of the human malaria parasite Plasmodium falciparum. J Biol Chem (2013) 0.92
Arginine-engrafted biodegradable polymer for the systemic delivery of therapeutic siRNA. Biomaterials (2011) 0.90
Silencing early viral replication in macrophages and dendritic cells effectively suppresses flavivirus encephalitis. PLoS One (2011) 0.89
Improved siRNA/shRNA functionality by mismatched duplex. PLoS One (2011) 0.89
Enhanced induction of HIV-specific cytotoxic T lymphocytes by dendritic cell-targeted delivery of SOCS-1 siRNA. Mol Ther (2010) 0.87
RNA interference-based therapeutics for human immunodeficiency virus HIV-1 treatment: synthetic siRNA or vector-based shRNA? Expert Opin Biol Ther (2010) 0.87
Antibody-mediated delivery of siRNAs for anti-HIV therapy. Methods Mol Biol (2011) 0.85
Long-term engraftment of human natural T regulatory cells in NOD/SCID IL2rγc(null) mice by expression of human IL-2. PLoS One (2012) 0.84
Site-specific Genome Editing in PBMCs With PLGA Nanoparticle-delivered PNAs Confers HIV-1 Resistance in Humanized Mice. Mol Ther Nucleic Acids (2013) 0.83
RNA-based gene therapy for the treatment and prevention of HIV: from bench to bedside. Yale J Biol Med (2011) 0.82
Single amino acid change in gp41 region of HIV-1 alters bystander apoptosis and CD4 decline in humanized mice. Virol J (2011) 0.82
Single chain variable fragment CD7 antibody conjugated PLGA/HDAC inhibitor immuno-nanoparticles: developing human T cell-specific nano-technology for delivery of therapeutic drugs targeting latent HIV. J Control Release (2011) 0.81
Effective suppression of HIV-1 by artificial bispecific miRNA targeting conserved sequences with tolerance for wobble base-pairing. Biochem Biophys Res Commun (2008) 0.81
Cross-clade CD8 T-cell responses to HIV(IIIB) and Chinese B' and C/B' viruses in North American and Chinese HIV-seropositive donors. J Acquir Immune Defic Syndr (2004) 0.80
Targeting the HIV entry, assembly and release pathways for anti-HIV gene therapy. Virology (2011) 0.78
Effective gene delivery into human stem cells with a cell-targeting Peptide-modified bioreducible polymer. Small (2014) 0.77
Organization of flaviviral replicase proteins in virus-induced membranes: a role for NS1' in Japanese encephalitis virus RNA synthesis. Novartis Found Symp (2006) 0.76
Targeting DNA vaccines to myeloid cells using a small peptide. Eur J Immunol (2014) 0.76
Cell-specific siRNA delivery by peptides and antibodies. Methods Enzymol (2012) 0.76
Delivering antiviral siRNA into human T-cells: New approaches in RNAi-based HIV therapy. IDrugs (2009) 0.75
Arginine-grafted biodegradable polymer: a versatile transfection reagent for both DNA and siRNA. Methods Mol Biol (2014) 0.75
Transfection of Mammalian Cells with Calcium Phosphate-DNA Coprecipitates. Cold Spring Harb Protoc (2019) 0.75
[The preparation of collagen sponge as tissue engineering scaffolds and analysis of its pore structure]. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi (2010) 0.75
Calcium Phosphate-Mediated Transfection of Adherent Cells or Cells Growing in Suspension: Variations on the Basic Method. Cold Spring Harb Protoc (2019) 0.75
Calcium Phosphate-Mediated Transfection of Cells with High-Molecular-Weight Genomic DNA. Cold Spring Harb Protoc (2019) 0.75
Assay for β-Galactosidase in Extracts of Mammalian Cells. Cold Spring Harb Protoc (2017) 0.75
Calcium Phosphate-Mediated Transfection of Eukaryotic Cells with Plasmid DNAs. Cold Spring Harb Protoc (2019) 0.75
Cationic cell-penetrating peptides as vehicles for siRNA delivery. Ther Deliv (2015) 0.75
β-Galactosidase. Cold Spring Harb Protoc (2017) 0.75